Printer Friendly

ALAMAR BIOSCIENCES ADDS MAJOR ANTIBIOTIC TO DIAGNOSTIC TEST KITS AFTER SECURING FDA CLEARANCE

 SACRAMENTO, Calif., July 15 /PRNewswire/ -- Alamar Biosciences, Inc. (NASDAQ: ALMR), a research and development company in the diagnostic product testing area, today announced it has received clearance from the U.S. Food and Drug Administration to add an important antibiotic to its disposable test kits. Ampicillin/sulbactam, a widely-used drug for treating respiratory, urinary and skin infections, is being added to the company's test kits to aid in determining which antibiotic and what dosage will be effective in treating gram positive bacterial infections.
 With the addition of ampicillin/sulbactam, manufactured by Pfizer Inc, Alamar now has 21 gram positive and 31 gram negative antibiotics cleared by the FDA, all of which are available for inclusion in its user-defined diagnostic kits.
 Currently, Alamar has five applications pending before the FDA, which relate to the company's bacterial identification test kit and a semi-automated test reading instrument. Once cleared, these two products will complete Alamar's initial product portfolio for manual and semi-automated bacterial identification and antibiotic susceptibility testing. This product portfolio will be capable of collectively addressing approximately two-thirds of an estimated $530 million market.
 Common stock in Alamar Biosciences, Inc. is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro (outside the body) testing products for hospitals, reference laboratories and other healthcare providers. Alamar also markets alamarBlue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 For information on Alamar Biosciences, Inc. by FAX, dial 1-800-PRO- INFO, extension 141.
 -0- 7/15/93
 /CONTACT: Mark Santor of Alamar Biosciences, Inc., 916-567-3475, or Elizabeth Truax of Financial Relations Board (San Francisco), 415-986-1591, for Alamar Biosciences, Inc./
 (ALMR)


CO: Alamar Biosciences, Inc. ST: California IN: MTC SU: PDT

TM -- NY008 -- 1781 07/15/93 09:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1993
Words:293
Previous Article:LEADING BREAST CANCER MEDICATION CLEARED FOR USE IN MEN NEW INDICATION OFFERS VALUABLE ALTERNATIVE TO SURGERY
Next Article:NATWEST BANCORP REPORTS RECORD PROFITS SIXTH CONSECUTIVE QUARTER OF INCREASED EARNINGS
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS
ALAMAR ANNOUNCES THE HIRING OF FIRST SALES FORCE
ALAMAR BIOSCIENCES ADDS MAJOR ANTIBIOTIC TO DIAGNOSTIC TEST KITS AFTER SECURING FDA CLEARANCE
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS
ALAMAR BIOSCIENCES ADDS 3NET SOFTWARE TO GROWING PRODUCT LINE
ALAMAR BIOSCIENCES TO PRESENT NEW METHOD FOR TESTING DRUG-RESISTANT TUBERCULOSIS AT ASM CONVENTION
ALAMAR BIOSCIENCES REPORTS THIRD QUARTER, NINE MONTHS RESULTS
ALAMAR BIOSCIENCES SECURES FDA CLEARANCE FOR READING INSTRUMENT; MOVES CLOSER TO COMPLETING PRODUCT LINE
ALAMAR BIOSCIENCES LAUNCHES PRODUCT LINE AFTER FDA CLEARANCE OF GRAM NEGATIVE BACTERIA ID TEST
ALAMAR BIOSCIENCES RECEIVES LAST PENDING FDA CLEARANCE; FULL PRODUCT LINE NOW AVAILABLE WORLDWIDE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters